| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1086-10MG | BCTC | 10mg | $126.00 | |
| GBM-1086-50MG | BCTC | 50mg | $536.00 |
| Bioassays Specification | |
| Bio-Activity | TRPV1 blocker |
| Chemical Name | 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide |
| Function / Pharmacology | Vanilloid receptor I (TRPV1) antagonist, IC50 = 35 nM for capsaicin-induced and 6 nM for acid-induced TRPV1 activation. Displays analgesic activity in rat models of neuropathic pain. Orally active and cell permeable. |
| CAS# | 393514-24-4 |
| MW | 372.9 |
| Molecular Formula | C20H25ClN4O |
| Solubility | Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Valenzano et al. (2003), N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties; J. Pharmacol. Exp. Ther., 306 377 / 2) Pomonis et al. (2003), N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain; J. Pharmacol. Exp. Ther., 306 387 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | TRPV1 blocker |
| Chemical Name | 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide |
| Function / Pharmacology | Vanilloid receptor I (TRPV1) antagonist, IC50 = 35 nM for capsaicin-induced and 6 nM for acid-induced TRPV1 activation. Displays analgesic activity in rat models of neuropathic pain. Orally active and cell permeable. |
| CAS# | 393514-24-4 |
| MW | 372.9 |
| Molecular Formula | C20H25ClN4O |
| Solubility | Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Valenzano et al. (2003), N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties; J. Pharmacol. Exp. Ther., 306 377 / 2) Pomonis et al. (2003), N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain; J. Pharmacol. Exp. Ther., 306 387 |
| Protein Specification | |
| Purity | >98% |
